# Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran

> **NCT01955720** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 46 (actual)

## Conditions studied

- Hemorrhage

## Interventions

- **DRUG:** BI 655075
- **DRUG:** BI 655075
- **DRUG:** Placebo
- **DRUG:** BI 655075
- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** BI 655075

## Key facts

- **NCT ID:** NCT01955720
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2014-05
- **Final completion:** 2014-08
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2016-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01955720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01955720, "Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01955720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*